ライフサイエンスコーパス: benign prostatic hyperplasia

1 ion-induced BSM hypertrophy, and in men with benign prostatic hyperplasia.

2 inflammation may be associated with LUTS and benign prostatic hyperplasia.

3 y used as a therapeutic for the treatment of benign prostatic hyperplasia.

4 ieve lower urinary tract symptoms related to benign prostatic hyperplasia.

5 echanical interaction of prostate cancer and benign prostatic hyperplasia.

6 gonist and ARI was used to treat symptomatic benign prostatic hyperplasia.

7 clearly related to prostatic enlargement or benign prostatic hyperplasia.

8 a-1A blocker prescribed for the treatment of benign prostatic hyperplasia.

9 t is not expressed in normal prostate nor in benign prostatic hyperplasia.

10 tions play a critical role in development of benign prostatic hyperplasia.

11 inary tract symptoms are often attributed to benign prostatic hyperplasia.

12 t of bladder outlet obstruction secondary to benign prostatic hyperplasia.

13 ot improve symptoms or objective measures of benign prostatic hyperplasia.

14 risk than nondaily NSAID users of developing benign prostatic hyperplasia.

15 e most rigorously analyzed interventions for benign prostatic hyperplasia.

16 prostate over other surgical treatments for benign prostatic hyperplasia.

17 SAID use may prevent or delay development of benign prostatic hyperplasia.

18 d with other surgical therapies for men with benign prostatic hyperplasia.

19 have a potential role in the pathogenesis of benign prostatic hyperplasia.

20 treatment of endometriosis, leiomyomas, and benign prostatic hyperplasia.

21 the appropriate management of a patient with benign prostatic hyperplasia.

22 sk factor for prostate cancer among men with benign prostatic hyperplasia.

23 ion of a patient with symptoms suggestive of benign prostatic hyperplasia.

24 muscle dysfunction, neurological factors and benign prostatic hyperplasia.

25 ases, including prostatic adenocarcinoma and benign prostatic hyperplasia.

26 y on measures of the clinical progression of benign prostatic hyperplasia.

27 role in the etiology of prostate cancer and benign prostatic hyperplasia.

28 of minimally invasive surgical therapies for benign prostatic hyperplasia.

29 line treatment for most men with symptomatic benign prostatic hyperplasia.

30 o be efficacious in reducing the symptoms of benign prostatic hyperplasia.

31 he latter in the context of the aetiology of benign prostatic hyperplasia.

32 lder with or without obstructive symptoms of benign prostatic hyperplasia.

33 r the past year in the medical management of benign prostatic hyperplasia.

34 et obstruction thought to be associated with benign prostatic hyperplasia.

35 way as it pertains to the pathophysiology of benign prostatic hyperplasia.

36 tatectomy became a widely used treatment for benign prostatic hyperplasia.

37 lar transition zone tissue of prostates with benign prostatic hyperplasia.

38 pment of BPSA-specific mAbs for the study of benign prostatic hyperplasia.

39 itiation, and to develop novel therapies for benign prostatic hyperplasia.

40 for alleviating urethral obstruction due to benign prostatic hyperplasia.

41 diseases such as myocardial hypertrophy and benign prostatic hyperplasia.

42 e combination of both drugs in 1229 men with benign prostatic hyperplasia.

43 onists will have utility in the treatment of benign prostatic hyperplasia.

44 of the spatial extent of prostate cancer and benign prostatic hyperplasia.

45 a variety of PCA specimens, cell lines, and benign prostatic hyperplasia.

46 or lower urinary tract symptoms secondary to benign prostatic hyperplasia.

47 ed here to differentiate prostate cancer and benign prostatic hyperplasia.

48 oups, 2 sex groups, and men with and without benign prostatic hyperplasia.

49 (5-ARIs) are widely used in the treatment of benign prostatic hyperplasia.

50 ells and a testosterone-induced rat model of benign prostatic hyperplasia.

51 wing transurethral resection of prostate for benign prostatic hyperplasia.

52 ved in stromal nodules associated with human benign prostatic hyperplasia.

53 ition zone cancers and glandular and stromal benign prostatic hyperplasia.

54 cy, safety, and long-term results of PAE for benign prostatic hyperplasia.

55 biopsy and improved the outcomes related to benign prostatic hyperplasia.

56 to relieve bladder outlet obstruction due to benign prostatic hyperplasia.

57 ior to other modalities for the treatment of benign prostatic hyperplasia.

58 over other surgical treatments for men with benign prostatic hyperplasia.

59 alues in regions of histologically confirmed benign prostatic hyperplasia (0.61 +/- 0.21 [standard de

60 secrete higher levels of IGF-1 and stimulate benign prostatic hyperplasia-1 cellular proliferation.

61 noma of the prostate (PCA), 15 patients with benign prostatic hyperplasia, 15 normal male subjects, a

62 complete loss of NKX3.1 expression in 5% of benign prostatic hyperplasias, 20% of high-grade prostat

63 was not significantly different from that of benign prostatic hyperplasia (4.8 +/- 2.01 [range, 1.8-8

64 Bacteremic patients were more likely to have benign prostatic hyperplasia (56% vs 19%; P = .04), a hi

65 stained positively in 0 of 12 (0%) cases of benign prostatic hyperplasia, 57 of 63 (90.5%) primary a

66 ry of prostate cancer, age at randomization, benign prostatic hyperplasia, age and stage at diagnosis

67 s frequently misdiagnosed as prostatitis and benign prostatic hyperplasia among men.

68 alpha-reductase inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, bu

69 Urinary complications resulting from benign prostatic hyperplasia and bladder outlet obstruct

70 Patients with symptomatic benign prostatic hyperplasia and cataracts requiring a u

71 discussed in relation to the pathogenesis of benign prostatic hyperplasia and future directions for r

72 specificity needed to differentiate PCa from benign prostatic hyperplasia and have high false positiv

73 he authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding p

74 being extensively used for the treatment of benign prostatic hyperplasia and in experimental setting

75 sely relate in predicting the progression of benign prostatic hyperplasia and in recent years increas

76 en in the United States for the treatment of benign prostatic hyperplasia and is commonly recommended

77 atment failure, or as definitive therapy for benign prostatic hyperplasia and its associated problems

78 cts that have been used for the treatment of benign prostatic hyperplasia and lower urinary tract sym

79 Besides the context of benign prostatic hyperplasia and lower urinary tract sym

80 ciated with significantly increased risks of benign prostatic hyperplasia and lower urinary tract sym

81 nd diet - for the prevention or treatment of benign prostatic hyperplasia and lower urinary tract sym

82 ortunity for the prevention and treatment of benign prostatic hyperplasia and lower urinary tract sym

83 alternatives within the context of standard benign prostatic hyperplasia and lower urinary tract sym

84 tor (AR) is associated with prostate cancer, benign prostatic hyperplasia and male infertility.

85 state tissue, with substantial expression in benign prostatic hyperplasia and prominent expression in

86 Both benign prostatic hyperplasia and prostate cancer are com

87 Benign prostatic hyperplasia and prostate cancer are oft

88 state, EMT processes have been implicated in benign prostatic hyperplasia and prostate cancer progres

89 previously linked to the development of both benign prostatic hyperplasia and prostate cancer.

90 ve function and/or altered susceptibility to benign prostatic hyperplasia and prostate cancer.

91 Macrophages are increased in human benign prostatic hyperplasia and prostate cancer.

92 provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.

93 common problems presenting to urologists are benign prostatic hyperplasia and sexual dysfunction, wit

94 ion in men with lower urinary tract symptoms/benign prostatic hyperplasia and the associated risk of

95 of therapy on the risk of surgery related to benign prostatic hyperplasia and the predictors of disea

96 cts that have been used for the treatment of benign prostatic hyperplasia and voiding dysfunction.

97 mation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract

98 the referent group after adjustment for age, benign prostatic hyperplasia, and family history.

99 nt for age, race/ethnicity, smoking history, benign prostatic hyperplasia, and family history.

100 rimary tissues derived from normal prostate, benign prostatic hyperplasia, and prostate carcinomas, I

101 n the luminal epithelium of normal prostate, benign prostatic hyperplasia, and prostatic intraepithel

102 the roles of 5 alpha-reductase inhibitors in benign prostatic hyperplasia, and these may expand furth

103 esults Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family hi

104 ars) and evaluated medications used to treat benign prostatic hyperplasia, anti-inflammatory drugs, a

105 Prostate cancer and benign prostatic hyperplasia are common genitourinary di

106 known that lower urinary tract symptoms and benign prostatic hyperplasia are definitely related to e

107 ion in men with lower urinary tract symptoms/benign prostatic hyperplasia are few and far between, bu

108 nary tract symptoms that are consistent with benign prostatic hyperplasia are not more likely to harb

109 blockers, commonly used for the treatment of benign prostatic hyperplasia, are associated with prosta

110 In benign prostatic hyperplasia, basal cells and areas of b

111 ergic drugs has been considered hazardous in benign prostatic hyperplasia because of concerns that th

112 pecificity for distinguishing early PCa from benign prostatic hyperplasia, because both PCa and benig

113 CR, while KGF expression was not detected in benign prostatic hyperplasia (BPH) (n = 6).

114 agonists with potential for the treatment of benign prostatic hyperplasia (BPH) (see part 1 of this s

115 were evaluated in relation to development of benign prostatic hyperplasia (BPH) among 29,386 members

116 he presence and progression of components of benign prostatic hyperplasia (BPH) and a clinical outcom

117 Benign prostatic hyperplasia (BPH) and associated lower

118 Benign prostatic hyperplasia (BPH) and associated lower

119 nhibitors (5-ARIs) are approved for treating benign prostatic hyperplasia (BPH) and have been found t

120 bladder outlet obstruction (PBOO) caused by benign prostatic hyperplasia (BPH) and in animal models

121 een the components of metabolic syndrome and benign prostatic hyperplasia (BPH) and lower urinary tra

122 ize-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tra

123 ificantly influence the risks of symptomatic benign prostatic hyperplasia (BPH) and lower urinary tra

124 ormones play prominent roles in the cause of benign prostatic hyperplasia (BPH) and lower urinary tra

125 ologically normal tissue (n = 51), including benign prostatic hyperplasia (BPH) and non-BPH samples,

126 Benign prostatic hyperplasia (BPH) and prostate adenocar

127 examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer r

128 tween periodontitis and prostate diseases of benign prostatic hyperplasia (BPH) and prostatitis is un

129 nes and high-grade clinical CaP (compared to benign prostatic hyperplasia (BPH) and well-differentiat

130 Chronic prostatitis (CPr) and benign prostatic hyperplasia (BPH) are complex inflammat

131 Although surrogate measures of benign prostatic hyperplasia (BPH) are often used in epi

132 Benign prostatic hyperplasia (BPH) as the main cause of

133 utrition seems to modify the pathogenesis of benign prostatic hyperplasia (BPH) effect symptomology i

134 r to discriminate prostatic inflammation and benign prostatic hyperplasia (BPH) from prostate cancer,

135 The understanding and therapy of benign prostatic hyperplasia (BPH) has become more compl

136 y examined dietary risk factors for incident benign prostatic hyperplasia (BPH) in 4,770 Prostate Can

137 Benign prostatic hyperplasia (BPH) in older men can caus

138 Benign prostatic hyperplasia (BPH) is a common cause of

139 Benign prostatic hyperplasia (BPH) is a common disease o

140 , lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) is a common medical p

141 Benign Prostatic Hyperplasia (BPH) is a complex conditio

142 rinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is a condition that c

143 Benign prostatic hyperplasia (BPH) is a disease of unkno

144 Background Benign prostatic hyperplasia (BPH) is a disease that aff

145 Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) is a highly prevalent

146 Benign prostatic hyperplasia (BPH) is a pathologic proli

147 Benign prostatic hyperplasia (BPH) is a prevalent age-re

148 Benign prostatic hyperplasia (BPH) is a progressive age-

149 The most prescribed class of medications for benign prostatic hyperplasia (BPH) is alpha-blockers (AB

150 Benign prostatic hyperplasia (BPH) is an age-related dis

151 Benign prostatic hyperplasia (BPH) is an extremely commo

152 Benign prostatic hyperplasia (BPH) is characterized by i

153 The etiology of benign prostatic hyperplasia (BPH) is multifactorial, an

154 Benign prostatic hyperplasia (BPH) is prevalent in old m

155 Benign prostatic hyperplasia (BPH) may decrease patient

156 umes of interest (VOIs) for prostate tumors, benign prostatic hyperplasia (BPH) nodules, prostatitis,

157 February 2019, 102 patients with symptoms of benign prostatic hyperplasia (BPH) not candidates for su

158 he effect of different treatment options for benign prostatic hyperplasia (BPH) on sexual function or

159 pecificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also

160 on of 112,152 medical records indicates that benign prostatic hyperplasia (BPH) prevalence is signifi

161 Benign prostatic hyperplasia (BPH) results in a signific

162 asm and nucleus of PCa samples; in contrast, benign prostatic hyperplasia (BPH) samples presented str

163 tate cancer cell lines, prostate cancer, and benign prostatic hyperplasia (BPH) tissues samples using

164 ofiling of primary human prostate cancer and benign prostatic hyperplasia (BPH) using cDNA microarray

165 Of the 35 benign prostatic hyperplasia (BPH), 25 (71.4%) specimens

166 Benign prostatic hyperplasia (BPH), a nonmalignant enlar

167 Current pharmacotherapies for symptomatic benign prostatic hyperplasia (BPH), an androgen receptor

168 d by bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH), an overactive bladde

169 roles in the development and progression of benign prostatic hyperplasia (BPH), but the underlying m

170 en variety is used in the initial therapy of benign prostatic hyperplasia (BPH), globally.

171 In a previous clinical pilot trial to treat benign prostatic hyperplasia (BPH), histotripsy did not

172 lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), the etiology of whic

173 In men treated with 5-ARI for treatment of benign prostatic hyperplasia (BPH), there was induction

174 ory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,73

175 of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the

176 inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the

177 s the second most common male neoplasia, and benign prostatic hyperplasia (BPH), which affects approx

178 h CPI-17 overexpression in BSM from men with benign prostatic hyperplasia (BPH)-induced bladder hyper

179 olization (TAE) as a potential treatment for benign prostatic hyperplasia (BPH).

180 osterone, have been used in the treatment of benign prostatic hyperplasia (BPH).

181 s a well known approach to the management of benign prostatic hyperplasia (BPH).

182 and differentiation might reduce the risk of benign prostatic hyperplasia (BPH).

183 y, urgency and incontinence in patients with benign prostatic hyperplasia (BPH).

184 ed with cells derived from normal tissues or benign prostatic hyperplasia (BPH).

185 (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH).

186 pecificity for distinguishing early PCa from benign prostatic hyperplasia (BPH).

187 1a) antagonists as a potential treatment for benign prostatic hyperplasia (BPH).

188 L-6 in the growth of prostatic carcinoma and benign prostatic hyperplasia (BPH).

189 ithin the PU after transurethral surgery for benign prostatic hyperplasia (BPH).

190 h are driving factors of voiding symptoms in benign prostatic hyperplasia (BPH).

191 mation has been suggested as an etiology for benign prostatic hyperplasia (BPH).

192 pecificity for distinguishing early PCa from benign prostatic hyperplasia (BPH).

193 n higher levels than cells representative of benign prostatic hyperplasia (BPH).

194 adder outlet procedures for the treatment of benign prostatic hyperplasia (BPH).

195 ation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).

196 rovide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH).

197 g lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clin

198 n held as the gold standard for treatment of benign prostatic hyperplasia (BPH); however, there has b

199 0), lymph node metastases (LNMs; n = 8), and benign prostatic hyperplasia (BPH; n = 6) with the use o

200 of the noncancerous disease categories (eg, benign prostatic hyperplasia [BPH], prostatic intraepith

201 gene expression of transformed [tumorigenic benign prostatic hyperplasia (BPH1)(CAFTD)] and parental

202 ow levels in normal prostatic epithelium and benign prostatic hyperplasia but significantly increased

203 nown to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which th

204 ing techniques in diagnosis and treatment of benign prostatic hyperplasia by reviewing the most recen

205 Men with benign prostatic hyperplasia can be treated with alpha 1

206 Overactive bladder and benign prostatic hyperplasia commonly cause lower urinar

207 The gold standard for surgical treatment of benign prostatic hyperplasia continues to be transurethr

208 Benign prostatic hyperplasia contributes to these mechan

209 Our simulations show that a history of benign prostatic hyperplasia creates mechanical stress f

210 , such as the need for invasive treatment of benign prostatic hyperplasia, development of a clinical

211 portant role in normal prostate development, benign prostatic hyperplasia, established prostate cance

212 o that in studies of dutasteride therapy for benign prostatic hyperplasia, except that in our study,

213 alternative for the treatment of symptomatic benign prostatic hyperplasia for men with prostates of a

214 ral resection of the prostate procedures for benign prostatic hyperplasia from 1983 to 2013 were coll

215 SA levels in the serum may help discriminate benign prostatic hyperplasia from early prostate cancer.

216 ecific antigen marker to better discriminate benign prostatic hyperplasia from early prostate cancer.

217 omy, interest in lasers for the treatment of benign prostatic hyperplasia has been rekindled.

218 cently, much of the available information on benign prostatic hyperplasia has come from randomized co

219 condary to benign prostatic obstruction from benign prostatic hyperplasia has proven to be an effecti

220 samples of normal-appearing prostate tissue, benign prostatic hyperplasia, high-grade prostatic intra

221 ncer progression stages, being detectable in benign prostatic hyperplasia, highly expressed in prosta

222 giographic procedure that effectively treats benign prostatic hyperplasia; however, PAE-related patie

223 studies and randomized controlled trials on benign prostatic hyperplasia in order to understand the

224 t largely undetectable in normal prostate or benign prostatic hyperplasia in vivo.

225 some history of intraprostatic injection for benign prostatic hyperplasia including the most recent r

226 oporosis is 1.1% and that for drugs to treat benign prostatic hyperplasia is 1-2%.

227 The surgical treatment of benign prostatic hyperplasia is a dynamic, evolving fiel

228 Although benign prostatic hyperplasia is an important cause of th

229 ey to obtaining optimal outcomes in men with benign prostatic hyperplasia is careful patient selectio

230 Benign prostatic hyperplasia is commonly treated with al

231 Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum co

232 their application in prostatic pathology and benign prostatic hyperplasia is not as clear.

233 The standard medical therapy for symptomatic benign prostatic hyperplasia is still alpha-blockers and

234 rgo comprehensive clinical evaluation before benign prostatic hyperplasia is treated, if indicated.

235 mportant roles in myocardial hypertrophy and benign prostatic hyperplasia, little is known about acut

236 fferent investigation modalities in men with benign prostatic hyperplasia/lower urinary tract symptom

237 of lower urinary tract symptom suggestive of benign prostatic hyperplasia (LUTS/BPH).

238 eeded before their place in the treatment of benign prostatic hyperplasia/LUTS can be properly assess

239 specific questions and counselling men with benign prostatic hyperplasia/LUTS.

240 Benign prostatic hyperplasia measures included developme

241 antigen (PSCA)in normal urogenital tissues, benign prostatic hyperplasia (n = 21), prostatic intraep

242 ed from 371 formalin-fixed blocks, including benign prostatic hyperplasia (n = 32) and primary tumors

243 ith urination, suggesting an exacerbation of benign prostatic hyperplasia; no other subject reported

244 helium (n = 48), hyperplasticepithelium from benign prostatic hyperplasia nodules (n = 22), PIA (n =

245 e evaluated, not when the prostatic capsule, benign prostatic hyperplasia nodules, or overall image q

246 The controls (benign prostatic hyperplasias, normal males, and normal

247 -induced myopathic bladder dysfunction (from benign prostatic hyperplasia or posterior urethral valve

248 s expressed by epithelial cells derived from benign prostatic hyperplasia or prostate cancer; thus, f

249 rinary tract symptom in men with symptomatic benign prostatic hyperplasia over alpha1-adrenergic anta

250 roved medical therapies for the treatment of benign prostatic hyperplasia over the past year, interes

251 high-grade prostate cancer when compared to benign prostatic hyperplasia (P<0.0001).

252 evelopments in the management of symptomatic benign prostatic hyperplasia, particularly the current r

253 ested more imaging studies than expected for benign prostatic hyperplasia patients in recent years, a

254 , inflammation was not related to LUTS or to benign prostatic hyperplasia progression.

255 o apply histotripsy to preclinical models of benign prostatic hyperplasia, prostate cancer, renal mas

256 ride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with fin

257 based on 105 prostate samples, consisting of benign prostatic hyperplasia regions and malignant tumor

258 steride has been shown to reduce and control benign prostatic hyperplasia-related haematuria, althoug

259 ute urinary retention or the requirement for benign prostatic hyperplasia-related surgery.

260 une 2018 in patients with moderate to severe benign prostatic hyperplasia-related symptoms.

261 prostatic hyperplasia, because both PCa and benign prostatic hyperplasia release PSA into the serum.

262 with prostatic artery embolization (PAE) for benign prostatic hyperplasia remains limited.

263 he prostate (TURP) has dominated symptomatic benign prostatic hyperplasia (s-BPH) surgical treatment

264 or-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.

265 Both proteins were present in benign prostatic hyperplasia samples.

266 ve surgical therapy for LUTS associated with benign prostatic hyperplasia seems attractive and may ha

267 Associations of prostatitis include benign prostatic hyperplasia, sexually transmitted disea

268 minimal initial evaluation of a patient with benign prostatic hyperplasia should include a thorough h

269 the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did

270 an immortalized PrEC line established from a benign prostatic hyperplasia specimen (BPH-1), and in th

271 lpha1-adrenergic antagonists for symptomatic benign prostatic hyperplasia, such as tamsulosin, increa

272 state, its expression is strongly reduced in benign prostatic hyperplasia suggesting that DAX-1 plays

273 In men with benign prostatic hyperplasia, terazosin was effective th

274 FOXO3a and PUMA is comparable and higher in benign prostatic hyperplasia than in prostate cancer Gle

275 d prevalence of lower urinary tract symptoms/benign prostatic hyperplasia, the incidence of acute uri

276 therapy for lower urinary tract symptoms and benign prostatic hyperplasia, the majority of the data a

277 rial to assess the safety of histotripsy for benign prostatic hyperplasia therapy.

278 tive p27Kip1 expression; acini in epithelial benign prostatic hyperplasia tissue contained more p27Ki

279 ue samples and cultured PC cells compared to benign prostatic hyperplasia tissue samples and normal p

280 atic epithelial cells, derived from tumor or benign prostatic hyperplasia tissue, were studied using

281 ip1-negative basal cells than acini from non-benign prostatic hyperplasia tissue.

282 stromal compartment of normal prostatic and benign prostatic hyperplasia tissue.

283 tissues is significantly higher than that in benign prostatic hyperplasia tissues, and PRMT5 expressi

284 ticularly in advanced prostate cancer versus benign prostatic hyperplasia tissues.

285 ity of prostate cancer, but not in normal or benign prostatic hyperplasia tissues.

286 years who had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment wi

287 For benign prostatic hyperplasia, transperineal and transure

288 ne aminotransferase (nine [6%] vs none), and benign prostatic hyperplasia (two [5%] vs none).

289 een androgen receptor gene polymorphisms and benign prostatic hyperplasia was investigated among 510

290 tionally, the gold standard for treatment of benign prostatic hyperplasia was the electrocautery-base

291 transurethral resection of the prostate for benign prostatic hyperplasia, we assessed serum, urine,

292 x 10(-3) mm(2)/sec) in glandular and stromal benign prostatic hyperplasia were 1.44 and 1.09, respect

293 ght eyes of 43 patients with newly diagnosed benign prostatic hyperplasia were included in this study

294 for men with bladder outlet obstruction from benign prostatic hyperplasia who are deemed high surgica

295 Benign prostatic hyperplasia with associated symptoms an

296 therapy for lower urinary tract symptoms and benign prostatic hyperplasia with either alpha adrenergi

297 ation was a safe and effective procedure for benign prostatic hyperplasia with good long-term results

298 sing minimally invasive surgical therapy for benign prostatic hyperplasia with increased attention fr

299 ts groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer

300 after prostate artery embolization (PAE) for benign prostatic hyperplasia with spherical particle pol